Price Alert

Xeris Biopharma Inc. (XERS)

NASDAQ: XERS · Real-Time Price · USD

7.54

0.24 (3.29%)

At close: Aug 15, 2025, 1:14 PM

3.29% (1D)

Bid	7.5
Market Cap	1.22B
Revenue (ttm)	246.03M
Net Income (ttm)	-32M
EPS (ttm)	-0.2
PE Ratio (ttm)	-37.67
Forward PE	56.83
Analyst	Buy

Ask	7.57
Volume	1,344,993
Avg. Volume (20D)	2,439,501
Open	7.29
Previous Close	7.30
Day's Range	7.21 - 7.58
52-Week Range	2.48 - 7.61
Beta	0.86

About XERS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol XERS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for XERS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Xeris Biopharma has released their quartely earnings on Aug 7, 2025:

Revenue of $71.54M exceeds estimates by $6.79M, with 48.84% YoY growth.

EPS of -0.01 exceeds estimates by 0.02, with 90.00% YoY growth.

Next Earnings Release

Xeris Biopharma Inc. is scheduled to release its earnings on Nov 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+20.22%

Xeris Biopharma Holdings shares are trading higher... Unlock content with Pro Subscription

2 months ago

-7.92%

Xeris Biopharma Holdings shares are trading lower. The company released Its strategy for long-term growth and value creation at 2025 analyst & investor day.

News

3 days ago · zacks.com

Xeris Biopharma (XERS) Upgraded to Buy: Here's Why

Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 days ago · zacks.com

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

1 week ago · seekingalpha.com

Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Comm...

1 week ago · fool.com

Xeris (XERS) Q2 Revenue Jumps 49%

1 week ago · zacks.com

Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street e...

1 week ago · zacks.com

Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates

Xeris Biopharma (XERS) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.1 per share a year ago.

1 week ago · businesswire.com

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...

2 weeks ago · businesswire.com

Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025

1 month ago · seekingalpha.com

Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing

Compared to other biotech companies, Xeris Biopharma Holdings Inc. is a company that has successfully launched products that are already generating revenue. As the company's revenue is expected to gro...

2 months ago · businesswire.com

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

Load More News